Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axsome Therapeutics, Inc.AXSM · Entity 2469 | Director | June 08, 2026 | June 11, 2026 |
| Flyte Aviation, Inc.RMED · Entity 8648 | Director | January 05, 2021 | January 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axsome Therapeutics, Inc.
Report date June 08, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,431 |
Reported balance
After 2026-06-08 transaction · row 1
1 source rowRow 1 · 2026-06-08 · Exercise / conversion · Acquired 1,429 · Balance 11,431 F1: On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant. F2: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-08 · Exercise / conversion · Disposed 1,429 · Balance 0 F2: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote. | 300 |
Reported balance
Holding disclosure · report date 2026-06-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 300 F3: Represents additional shares held indirectly by the Reporting Person prior to June 10, 2026, which includes shares indirectly beneficially owned by Mr. Saad as custodian for his children's UTMA accounts. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant.
F2: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F3: Represents additional shares held indirectly by the Reporting Person prior to June 10, 2026, which includes shares indirectly beneficially owned by Mr. Saad as custodian for his children's UTMA accounts.
Flyte Aviation, Inc.
Report date January 05, 2021 · Filed January 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,750 |
Reported balance
After 2021-01-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-01-05 · Grant · Acquired 8,227 · Balance 13,750 F1: The Reporting Person has elected to receive his 2021 retainer compensation in restricted stock, rather than cash. Subject to the Reporting Person continuing to be a "Service Provider" (as defined in the Company's 2018 Equity Incentive Plan) through each vesting date, the shares shall vest as follows: 25% of the shares subject to the restricted stock award shall vest quarterly on the fifth of the month immediately following the end of the quarter corresponding with the date of grant (i.e. April 5, 2021, July 5, 2021, October 5, 2021, and January 5, 2022), such that the shares shall be fully vested on January 5, 2022. F2: On November 16, 2020, the common stock of the company reverse-split 25-for-1, resulting in the reporting persons ownership being reduced by 132,562. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person has elected to receive his 2021 retainer compensation in restricted stock, rather than cash. Subject to the Reporting Person continuing to be a "Service Provider" (as defined in the Company's 2018 Equity Incentive Plan) through each vesting date, the shares shall vest as follows: 25% of the shares subject to the restricted stock award shall vest quarterly on the fifth of the month immediately following the end of the quarter corresponding with the date of grant (i.e. April 5, 2021, July 5, 2021, October 5, 2021, and January 5, 2022), such that the shares shall be fully vested on January 5, 2022.
F2: On November 16, 2020, the common stock of the company reverse-split 25-for-1, resulting in the reporting persons ownership being reduced by 132,562.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2026 Filed Jun 11, 2026 01:49 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionRestricted Stock Units · Derivative | 1,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-266436 · ownership.xml · derivative · entry 3 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,429 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · derivative.expiration_date: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| June 08, 2026 Filed Jun 11, 2026 01:49 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 1,429 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-266436 · ownership.xml · nonDerivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant. F2 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:16 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 1,721 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-264034 · ownership.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,721 Underlying: Common Stock · 1,721 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest in full on the one-year anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs vest in full on the one-year anniversary of the date of grant. Read SEC document |
| December 31, 2025 Filed Jan 3, 2026 00:02 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 31,346 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001193125-26-001181 · ownership.xml · derivative · entry 7 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,346 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| December 31, 2025 Filed Jan 3, 2026 00:02 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,231 | $0.00 Strike: $8.02 | $0.00 |
DisclosureSEC source: 0001193125-26-001181 · ownership.xml · derivative · entry 6 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,231 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| December 31, 2025 Filed Jan 3, 2026 00:02 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 31,346 | $165.18 | $5,177,732.28 |
DisclosureSEC source: 0001193125-26-001181 · ownership.xml · nonDerivative · entry 4 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,002 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $165.00 and $166.09. Read SEC document |
| December 31, 2025 Filed Jan 3, 2026 00:02 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 31,346 | $4.95 | $155,162.70 |
DisclosureSEC source: 0001193125-26-001181 · ownership.xml · nonDerivative · entry 3 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| December 31, 2025 Filed Jan 3, 2026 00:02 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 6,231 | $165.18 | $1,029,236.58 |
DisclosureSEC source: 0001193125-26-001181 · ownership.xml · nonDerivative · entry 2 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,002 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $165.00 and $166.09. Read SEC document |
| December 31, 2025 Filed Jan 3, 2026 00:02 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 6,231 | $8.02 | $49,972.62 |
DisclosureSEC source: 0001193125-26-001181 · ownership.xml · nonDerivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| September 05, 2025 Filed Sep 5, 2025 23:43 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,127 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0000950170-25-113311 · ownership.xml · derivative · entry 4 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,127 shares Expires 2025-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within the next two months. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed. Read SEC document |
| September 05, 2025 Filed Sep 5, 2025 23:43 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 9,127 | $125.07 | $1,141,513.89 |
DisclosureSEC source: 0000950170-25-113311 · ownership.xml · nonDerivative · entry 2 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,002 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $125.00 and $125.22. Read SEC document |
| September 05, 2025 Filed Sep 5, 2025 23:43 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 9,127 | $9.00 | $82,143.00 |
DisclosureSEC source: 0000950170-25-113311 · ownership.xml · nonDerivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,129 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within the next two months. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 1,429 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-084555 · ownership.xml · derivative · entry 2 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,429 Underlying: Common Stock · 1,429 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest in full on the one-year anniversary of the date of grant, June 6, 2026. F3 · derivative.expiration_date: The RSUs vest in full on the one-year anniversary of the date of grant, June 6, 2026. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 3,166 | $0.00 Strike: $111.91 | $0.00 |
DisclosureSEC source: 0000950170-25-084555 · ownership.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,166 Underlying: Common Stock · 3,166 shares Expires 2035-06-06 F1 · derivative.exercise_date: The options vest in full on the one-year anniversary of the date of grant, June 6, 2026. Read SEC document |
| February 21, 2025 Filed Feb 26, 2025 00:59 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 1,494 | $0.00 Strike: $137.75 | $0.00 |
DisclosureSEC source: 0000950170-25-027076 · ownership.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,494 Underlying: Common Stock · 1,494 shares Expires 2035-02-20 F1 · shares: Represents 1,494 options elected to be received in lieu of cash compensation earned in 2024. All of such options are immediately exercisable. Read SEC document |
| September 11, 2024 Filed Sep 11, 2024 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,016 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0000950170-24-105616 · ownership.xml · derivative · entry 4 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,016 shares Expires 2024-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur later this month. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| September 11, 2024 Filed Sep 11, 2024 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 11,016 | $91.31 | $1,005,870.96 |
DisclosureSEC source: 0000950170-24-105616 · ownership.xml · nonDerivative · entry 2 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,002 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $90.25 and $92.90. Read SEC document |
| September 11, 2024 Filed Sep 11, 2024 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 11,016 | $3.67 | $40,428.72 |
DisclosureSEC source: 0000950170-24-105616 · ownership.xml · nonDerivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur later this month. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 5,799 | $0.00 Strike: $73.90 | $0.00 |
DisclosureSEC source: 0000950170-24-071961 · ownership.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,799 Underlying: Common Stock · 5,799 shares Expires 2034-06-07 F1 · derivative.exercise_date: The options vest in full on the one-year anniversary of the date of grant, June 7, 2025. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:34 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 1,519 | $0.00 Strike: $84.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023374 · ownership.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,519 Underlying: Common Stock · 1,519 shares Expires 2034-02-26 F1 · shares: Represents 1,519 options elected to be received in lieu of cash compensation earned in 2023. All of such options are immediately exercisable. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 22:22 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 5,681 | $0.00 Strike: $74.12 | $0.00 |
DisclosureSEC source: 0001209191-23-034850 · doc4.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,681 Underlying: Common Stock · 5,681 shares Expires 2033-06-02 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, June 2, 2024. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:12 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 2,224 | $0.00 Strike: $65.32 | $0.00 |
DisclosureSEC source: 0001209191-23-016453 · doc4.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,224 Underlying: Common Stock · 2,224 shares Expires 2033-03-01 F1 · shares: Represents 2,224 options elected to be received in lieu of cash compensation earned in 2022. All of such options are immediately exercisable. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 20:08 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 16,976 | $0.00 Strike: $25.53 | $0.00 |
DisclosureSEC source: 0001209191-22-034826 · doc4.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,976 Underlying: Common Stock · 16,976 shares Expires 2032-06-03 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, June 3, 2023. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 22:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 2,337 | $0.00 Strike: $29.91 | $0.00 |
DisclosureSEC source: 0001209191-22-017153 · doc4.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,337 Underlying: Common Stock · 2,337 shares Expires 2032-03-03 F1 · shares: Represents 2,337 options elected to be received in lieu of cash compensation earned in 2021. All of such options are immediately exercisable. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 12:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 100 | $34.40 | $3,440.00 |
DisclosureSEC source: 0001209191-21-065696 · doc4.xml · nonDerivative · entry 4 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Custodial account for child Disclosed balance after: 100 F1 · ownership.nature: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 12:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 100 | $34.45 | $3,445.00 |
DisclosureSEC source: 0001209191-21-065696 · doc4.xml · nonDerivative · entry 3 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Custodial account for child Disclosed balance after: 100 F1 · ownership.nature: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 12:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 100 | $34.40 | $3,439.50 |
DisclosureSEC source: 0001209191-21-065696 · doc4.xml · nonDerivative · entry 2 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Custodial account for child Disclosed balance after: 100 F1 · ownership.nature: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 12:30 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 3,000 | $34.53 | $103,597.20 |
DisclosureSEC source: 0001209191-21-065696 · doc4.xml · nonDerivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,002 Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:52 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 7,325 | $0.00 Strike: $61.32 | $0.00 |
DisclosureSEC source: 0001209191-21-038955 · doc4.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,325 Underlying: Common Stock · 7,325 shares Expires 2031-06-04 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, June 4, 2022. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 02:47 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 1,241 | $0.00 Strike: $65.02 | $0.00 |
DisclosureSEC source: 0000899243-21-010809 · doc4.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,241 Underlying: Common Stock · 1,241 shares Expires 2031-03-04 F1 · shares: Represents 1,241 options elected to be received in lieu of cash compensation earned in 2020. All of such options are immediately exercisable. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 23:08 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | GrantCommon Stock | 8,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002576 · doc4.xml · nonDerivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 F1 · shares: The Reporting Person has elected to receive his 2021 retainer compensation in restricted stock, rather than cash. Subject to the Reporting Person continuing to be a "Service Provider" (as defined in the Company's 2018 Equity Incentive Plan) through each vesting date, the shares shall vest as follows: 25% of the shares subject to the restricted stock award shall vest quarterly on the fifth of the month immediately following the end of the quarter corresponding with the date of grant (i.e. April 5, 2021, July 5, 2021, October 5, 2021, and January 5, 2022), such that the shares shall be fully vested on January 5, 2022. F2 · balance_after: On November 16, 2020, the common stock of the company reverse-split 25-for-1, resulting in the reporting persons ownership being reduced by 132,562. Read SEC document |
| October 12, 2020 Filed Oct 14, 2020 21:54 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054820 · doc4.xml · nonDerivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,085 F1 · shares: Reported shares represents a grant of restricted stock awards (the "RSAs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock award represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSAs will vest on the earlier of (i) October 12, 2021, or (ii) the day prior to the date of the Annual Meeting next following October 12, 2020, subject to the reporting person's continued service. Read SEC document |
| June 05, 2020 Filed Jun 5, 2020 22:42 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $77.38 | $0.00 |
DisclosureSEC source: 0001179110-20-007058 · edgar.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2030-06-05 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, June 5, 2021. Read SEC document |
| March 17, 2020 Filed Mar 20, 2020 01:17 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 3,789 | $0.00 Strike: $45.14 | $0.00 |
DisclosureSEC source: 0001179110-20-004006 · edgar.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,789 Underlying: Common Stock · 3,789 shares Expires 2030-03-16 F1 · shares: Represents 3,789 options elected to be received in lieu of cash compensation earned in 2019. All of such options are immediately exercisable. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 22:44 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | GrantStock Option (Right to Buy) · Derivative | 49,576 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001209191-20-002586 · doc4.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,576 Underlying: Common Stock · 49,576 shares Expires 2030-01-06 F1 · derivative.exercise_date: The Reporting Person has elected to receive his 2020 retainer compensation in stock option grants, rather than cash. Subject to the Reporting Person continuing to be a "Service Provider" (as defined in the Company's 2018 Equity Incentive Plan) through each vesting date, the shares shall vest as follows: 25% of the shares subject to the option shall vest quarterly on the fifth of the month immediately following the end of the quarter corresponding with the date of grant (i.e. April 5, 2020, July 5, 2020, October 5, 2020, and January 5, 2021), such that the shares shall be fully vested on January 5, 2021. Read SEC document |
| June 07, 2019 Filed Jun 10, 2019 22:21 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $22.03 | $0.00 |
DisclosureSEC source: 0001104659-19-034643 · a4.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-07 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, June 7, 2020. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 21:55 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | GrantCommon Stock | 29,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035637 · doc4.xml · nonDerivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,085 F1 · shares: Reported shares represents a grant of restricted stock units (the "RSUs") pursuant to Ra Medical Systems, Inc.'s 2018 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Ra Medical Systems, Inc. common stock. The RSUs will vest on the earlier of (i) June 6, 2020, or (ii) the day prior to the date of the Annual Meeting next following June 6, 2019, subject to the reporting person's continued service. Read SEC document |
| May 23, 2019 Filed May 24, 2019 11:19 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 3,500 | $22.33 | $78,155.00 |
DisclosureSEC source: 0001179110-19-006616 · edgar.xml · nonDerivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,002 F1 · price: The price reported in Column 4 is an average price. These shares were purchased by the reporting person in multiple transactions at prices ranging from $22.30 to $22.35, inclusive. The reporting person undertakes to provide to Axsome Therapeutics, Inc., the staff of the Securities and Exchange Commission, and others pursuant to applicable securities laws, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:07 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 29,387 | $0.00 Strike: $12.95 | $0.00 |
DisclosureSEC source: 0001104659-19-016572 · a4.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,387 Underlying: Common Stock · 29,387 shares Expires 2029-03-18 F1 · shares: Represents 29,387 options elected to be received in lieu of cash compensation earned in 2018. All of such options are immediately exercisable. Read SEC document |
| October 04, 2018 Filed Oct 5, 2018 22:08 UTC | Flyte Aviation, Inc. RMED · Entity 8648 | GrantCommon Stock | 8,235 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-054435 · doc4.xml · nonDerivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,235 F1 · shares: Reported shares are represented by restricted stock units ("RSUs"), and each RSU is the economic equivalent of one share of Ra Medical Systems, Inc. common stock. 1/3rd of the RSUs shall vest annually beginning on October 4, 2019 such that the RSUs will be fully vested on October 4, 2021, subject to the reporting person's continued service. Read SEC document |
| June 01, 2018 Filed Jun 6, 2018 00:21 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Options (right to buy) · Derivative | 13,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001104659-18-038399 · a4.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2028-06-01 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, June 1, 2019. Read SEC document |
| March 12, 2018 Filed Apr 5, 2018 14:05 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 32,602 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001104659-18-022601 · a4.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,602 Underlying: Common Stock · 32,602 shares Expires 2028-03-11 F1 · shares: Represents 32,602 options elected to be received in lieu of cash compensation earned in 2017. All of such options are immediately exercisable. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 20:55 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001104659-17-017639 · a4.xml · derivative · entry 2 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-03-14 F2 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, March 15, 2018. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 20:55 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 31,346 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001104659-17-017639 · a4.xml · derivative · entry 1 Saad Mark E · CIK 0001295913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,346 Underlying: Common Stock · 31,346 shares Expires 2027-03-14 F1 · shares: Represents 11,000 options granted as compensation for service during 2016 and 20,346 options elected to be received in lieu of cash compensation earned in 2016. All of such options are immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.